Suppr超能文献

内容效度——在新开发的用于医疗产品评估的患者报告结局(PRO)工具中建立和报告证据:ISPOR PRO 良好研究实践工作组报告:第 2 部分——评估受访者的理解。

Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.

机构信息

Department of Health Services, University of Washington, Seattle, WA 98195-9455, USA.

出版信息

Value Health. 2011 Dec;14(8):978-88. doi: 10.1016/j.jval.2011.06.013. Epub 2011 Oct 10.

Abstract

The importance of content validity in developing patient reported outcomes (PRO) instruments is stressed by both the US Food and Drug Administration and the European Medicines Agency. Content validity is the extent to which an instrument measures the important aspects of concepts developers or users purport it to assess. A PRO instrument measures the concepts most relevant and important to a patient's condition and its treatment. For PRO instruments, items and domains as reflected in the scores of an instrument should be important to the target population and comprehensive with respect to patient concerns. Documentation of target population input in item generation, as well as evaluation of patient understanding through cognitive interviewing, can provide the evidence for content validity. Part 1 of this task force report covers elicitation of key concepts using qualitative focus groups and/or interviews to inform content and structure of a new PRO instrument. Building on qualitative interviews and focus groups used to elicit concepts, cognitive interviews help developers craft items that can be understood by respondents in the target population and can ultimately confirm that the final instrument is appropriate, comprehensive, and understandable in the target population. Part 2 details: 1) the methods for conducting cognitive interviews that address patient understanding of items, instructions, and response options; and 2) the methods for tracking item development through the various stages of research and preparing this tracking for submission to regulatory agencies. The task force report's two parts are meant to be read together. They are intended to offer suggestions for good practice in planning, executing, and documenting qualitative studies that are used to support the content validity of PRO instruments to be used in medical product evaluation.

摘要

美国食品和药物管理局以及欧洲药品管理局均强调了内容效度在开发患者报告结局(PRO)工具中的重要性。内容效度是指工具在多大程度上测量了开发者或使用者声称要评估的概念的重要方面。PRO 工具测量与患者病情及其治疗最相关和最重要的概念。对于 PRO 工具而言,反映在工具得分中的项目和领域应该与目标人群有关,并且全面涵盖患者关注的问题。通过生成项目的定性焦点小组和/或访谈来记录目标人群的投入,以及通过认知访谈评估患者的理解,可以为内容效度提供证据。本工作组报告的第 1 部分涵盖了使用定性焦点小组和/或访谈来获取关键概念,以告知新 PRO 工具的内容和结构。在用于获取概念的定性访谈和焦点小组的基础上,认知访谈有助于开发人员精心设计可以被目标人群中的受访者理解的项目,并最终确认最终工具在目标人群中是适当的、全面的和可理解的。第 2 部分详细介绍了:1)进行认知访谈的方法,以解决患者对项目、说明和应答选项的理解问题;以及 2)通过研究的各个阶段跟踪项目开发的方法,并为向监管机构提交此跟踪信息做好准备。本工作组报告的两部分旨在一并阅读。它们旨在为计划、执行和记录用于支持在药物产品评估中使用的 PRO 工具的内容效度的定性研究提供良好实践的建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验